Isocitrate dehydrogenase type i mutation as a prognostic factor in glioblastoma and a literature review;Importancia de la mutación de la isocitrato deshidrogenasa tipo I como factor pronóstico en pacientes con glioblastomas y revisión de la literatura

Neurocirugia

Volumn 26, Issue 6, 2015, Pages 276-283

  De Quintana Schmidt, Cristian ^a   Alvarez Holzapfel, María Jesús ^a   Nomdedeu Guinot, Josep ^a   Bague Rosell, Silvia ^a   Gallego Rubio, Oscar ^a   Leidinger, Andreas ^a   Salgado Lopez, Laura ^a   Molet Teixidó, Joan ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Genetic markers; Glioblastoma; Glioma; IDH; Isocitrate dehydrogenase; Prognosis; Survival

Indexed keywords

BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE TYPE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; GENE MUTATION; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BRAIN TUMOR; GENETICS; MUTATION; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84947027384     PISSN: 11301473     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neucir.2015.04.001     Document Type: Article

References (40)

1. H. Ohgaki, and P. Kleihues Epidemiology and etiology of gliomas Acta Neuropathol. 109 2005 93 108
2. R. Ma, N. de Pennington, M. Hofer, C. Blesing, and R. Stacey Diagnostic and prognostic markers in gliomas. An update Br J Neurosurg. 27 2013 311 315
3. R. Helseth, E. Helseth, T.B. Johannesen, C.W. Langberg, K. Lote, P. Rønning, and et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme Acta Neurol Scand. 122 2010 159 167
4. M. Lacroix, D. Abi-Said, D.R. Fourney, Z.L. Gokaslan, W. Shi, F. DeMonte, and et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg. 95 2001 190 198
5. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvet, and et al. The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 114 2007 97 109
6. M. Ohno, Y. Narita, Y. Miyakita, Y. Okita, Y. Matsushita, A. Yoshida, and et al. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status Brain Tumor Pathol. 29 2012 183 191
7. A. Lai, S. Kharbanda, W.B. Pope, A. Tran, O.E. Solis, F. Peale, and et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin J Clin Oncol 29 2011 4482 4490
8. K. Ichimura Molecular pathogenesis of IDH mutations in gliomas Brain Tumor Pathol. 29 2012 131 139
9. M. Weller, R. Stupp, M.E. Hegi, M. van den Bent, J.C. Tonn, M. Sanson, and et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice Neuro-Oncology. 14 Suppl 4 2012 100 108
10. H. Jiang, X. Ren, X. Cui, J. Wang, W. Jia, Z. Zhou, and et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas Neuro-Oncology. 15 2013 775 782
11. Y. Wang, and T. Jiang Understanding high grade glioma: molecular mechanism, therapy and comprehensive management Cancer Letters. 331 2013 139 146
12. D.E. Reuss, F. Sahm, D. Schrimpf, B. Wiestler, D. Capper, C. Koelsche, and et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma Acta Neuropathol. 129 2015 133 146
13. J. Cai, P. Yang, C. Zhang, W. Zhang, Y. Liu, Z. Bao, and et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples Oncotarget. 5 2014 2551 2561
14. S. Agarwal, M.C. Sharma, P. Jha, P. Pathak, V. Suri, C. Sarkar, and et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing Neuro-Oncology. 15 2013 718 726
15. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, P. Angenendt, and et al. An integrated genomic analysis of human glioblastoma multiforme Science. 321 2008 1807 1812
16. N.K. Kloosterhof, L.B. Bralten, H.J. Dubbink, P.J. French, and M.J. van den Bent Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncology. 12 2010 83 91
17. P. Zou, H. Xu, P. Chen, Q. Yan, L. Zhao, P. Zhao, and et al. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis PLoS One. 8 2013 e68782
18. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, and et al. IDH1 and IDH2 mutations in gliomas N Engl J Med. 360 2009 Feb 19 765 773
19. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. Deimling Analysis of the IDH1 codon 132 mutation in brain tumors Acta Neuropathol. 116 2008 597 602
20. S. Leu, S. Felten von, S. Frank, E. Vassella, I. Vajtai, E. Taylor, and et al. IDH/MGMT driven molecular classification of low-grade glioma is a strong predictor for long-term survival Neuro-Oncology. 15 2013 469 479
21. M. Ohno, Y. Narita, Y. Miyakita, Y. Matsushita, A. Yoshida, S. Fukushima, and et al. Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas Brain Tumor Pathol. 30 2013 224 232
22. C. Gozé, C. Bezzina, E. Gozé, V. Rigau, T. Maudelonde, L. Bauchet, and et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth J Neurooncol. 108 2012 69 75
23. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol. 174 2010 1149 1153
24. B.C. Christensen, A.A. Smith, S. Zheng, D.C. Koestler, E.A. Houseman, C.J. Marsit, and et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma J Natl Cancer Inst. 103 2011 143 153
25. J. Laffaire, S. Everhard, A. Idbaih, E. Crinière, Y. Marie, A. de Reyniès, and et al. Methylation pro- filing identifies 2 groups of gliomas according to their tumorigenesis Neurooncology. 13 2011 84 98
26. H. Noushmehr, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell. 17 2010 510 522
27. P. De Bonis, C. Anile, A. Pompucci, A. Fiorentino, M. Balducci, S. Chiesa, and et al. The influence of surgery on recurrence pattern of glioblastoma Clin Neurol Neurosurg. 115 2013 37 43
28. W. Stummer, H-J. Reulen, T. Meinel, U. Pichlmeier, W. Schumacher, J-C. Tonn, and et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias Neurosurgery. 62 2008 564 576
29. T.A. Juratli, M. Kirsch, K. Robel, S. Soucek, K. Geiger, R. Kummer, and et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas J Neurooncol. 108 2012 403 410
30. C. Houillier, X. Wang, G. Kaloshi, and K. Mokhtari IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology. 75 2010 1560 1566
31. S. Nobusawa, T. Watanabe, P. Kleihues, and H.I.D.H1 Ohgaki Mutations as molecular signature and predictive factor of secondary glioblastomas Clin Cancer Res. 15 2009 6002 6007
32. T.A. Juratli, M. Peitzsch, K. Geiger, G. Schackert, G. Eisenhofer, and D. Krex Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas Neuro-Oncology. 15 2013 682 690
33. A.L. Cohen, S.L. Holmen, and H. Colman IDH1 and IDH2 mutations in gliomas Curr Neurol Neurosci Rep. 13 2013 345
34. B. Boisselier, J. Gállego Pérez-Larraya, M. Rossetto, M. Labussière, P. Ciccarino, Y. Marie, and et al. Detection of IDH1 mutation in the plasma of patients with glioma Neurology. 79 2012 1693 1698
35. D. Gorovets, K. Kannan, R. Shen, E.R. Kastenhuber, N. Islamdoust, C. Campos, and et al. IDH Mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma Clinical Cancer Research. 18 2012 2490 2501
36. D. Capper, M. Simon, C.D. Langhans, J.G. Okun, J.C. Tonn, M. Weller, and et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size Int J Cancer. 131 2012 766 768
37. O.C. Andronesi, G.S. Kim, E. Gerstner, T. Batchelor, A.A. Tzika, V.R. Fantin, and et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2 D correlation magnetic resonance spectroscopy Sci Transl Med. 4 2012 116ra4
38. O.C. Andronesi, O. Rapalino, E. Gerstner, A. Chi, T.T. Batchelor, D.P. Cahill, and et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate J Clin Invest 123 2013 3659 3663
39. C. Choi, S.K. Ganji, R.J. DeBerardinis, K.J. Hatanpaa, D. Rakheja, Z. Kovacs, and et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas Nat Med. 18 2012 624 629
40. J. Li, M. Wang, M. Won, E.G. Shaw, C. Coughlin, W.R. Curran Jr., and et al. Validation and simplification of the radiation therapy oncology group recursive partitioning analysis classification for glioblastoma Int J Radiat Oncol Biol Phys. 81 2011 623 630